Search Results

You are looking at 91 - 100 of 116 items for :

  • "novel therapy" x
  • All content x
Clear All
Full access

Amit Mahipal, Minsig Choi, and Richard Kim

development of novel therapies for the second-line treatment of advanced gastric cancer Discuss the clinical data supporting the use of currently approved and emerging targeted therapies in the second-line setting Gastric cancer is the fourth most

Full access

Pamela S. Becker

Transplant 2012 ; 18 : 314 – 317 43. Pozotrigo M Adel N Landau H . Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center

Full access

Mauro P. Avanzi and Renier J. Brentjens

this novel therapy. In the past few years, a significant number of clinical trials have shown unprecedented success in the treatment of NHL using T cells, mostly with CD19 as a target. The comparison between different co-stimulatory domains (CD28 vs 4

Full access

Kristen Keon Ciombor and Tanios Bekaii-Saab

more comprehensive CRC genotyping and studies of tumor mutational effects on treatment efficacy. In terms of developing novel therapies against these tumor subtypes, treatment of BRAF -mutated CRC with BRAF inhibitor monotherapy has not been as

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacalyn Rosenblatt, Irene M. Ghobrial, Robert L. Schlossman, David Avigan, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson

after transplantation for myeloma: final analysis of the IFM 2005-02 [abstract] . Blood 2010 ; 116 : Abstract 310 . 18 Kumar SK Rajkumar SV Dispenzieri A . Improved survival in multiple myeloma and the impact of novel therapies . Blood

Full access

Alessandra Larocca and Antonio Palumbo

multiple myeloma . Blood 2008 ; 111 : 2521 – 2526 . 3 Kumar SK Rajkumar SV Dispenzieri A . Improved survival in multiple myeloma and the impact of novel therapies . Blood 2008 ; 111 : 2516 – 2520 . 4 Durie BG Kyle RA Belch A

Full access

Erich M. Sturgis and K. Kian Ang

deintensification should be conducted in closely monitored clinical trials. Achieving reduced toxicity will either require reducing the extent and impact of current therapies or adopting novel therapies with inherently less toxicity. Because cancer cure remains

Full access

Xiuning Le, Renata Ferrarotto, Trisha Wise-Draper, and Maura Gillison

novel therapy combinations or novel immunotherapy strategies are desperately needed. Many immunotherapy combinations have been tested in R/M SCCHN to evaluate whether adding a second or third immune checkpoint blockade can enhance anti–PD-1/L1 efficacy

Full access

-positive OPSCC. However, the cure rates for HPV-negative tumors remain poor, and CRT regimens are highly toxic and immunosuppressive. As a result, novel therapies are required to minimize toxicity, modulate immunosuppression, and further improve outcomes

Full access

Alan P. Venook, Maria E. Arcila, Al B. Benson III, Donald A. Berry, David Ross Camidge, Robert W. Carlson, Toni K. Choueiri, Valerie Guild, Gregory P. Kalemkerian, Razelle Kurzrock, Christine M. Lovly, Amy E. McKee, Robert J. Morgan, Anthony J. Olszanski, Mary W. Redman, Vered Stearns, Joan McClure, and Marian L. Birkeland

determine and refine diagnoses; in the determination of prognosis, including the prediction of relapse, disease progression, and survival; and as markers to predict response to therapy, including hormone therapies, chemotherapy, and other novel therapy